ST. LOUIS, MO – October 26, 2010 – Tripos®, a leading provider of drug discovery

informatics products and services, today announced the release and general availability

of SYBYL-X Version 1.2. This new release focuses on streamlined workflows for life

science researchers, with the addition of a new, project-oriented interface for QSAR

studies, from obtaining data to delivering findings, suitable for the QSAR novice and

expert alike. Additionally, researchers benefit from improvements to docking with the

addition of Surflex-Dock’s fragment-constrained docking and treatment of protein

flexibility.

Tripos’ SYBYL-X product manager and lead scientist, Brian B. Masek, Ph.D., said,

“Tripos has been the industry leader in 3D QSAR since the inception of Comparative

Molecular Field Analysis (CoMFA), which is cited in literally thousands of peer-reviewed

research publications, and we’ve continued at the forefront of 3D QSAR science with

the recent release of the next generation of 3D QSAR, with Topomer CoMFA, allowing

3D QSAR predictions to be used for R-group virtual screening.”

According to Dr. Masek, “The introduction of the new QSAR project manager really

brings accessibility of CoMFA to a new level, simplifying the entire workflow from

structure preparation and training/test set selection all the way through to delivering

results. Customers are very excited, reporting that using the new project manager, they

have much higher reproducibility and interpretation of experiments started or run days

or even months earlier, and that the packaging and structuring of the workflow really

makes them more productive. Additionally, the docking enhancements allow scientists

to more closely approximate real-world conditions with the addition of treatment of

protein flexibility, and to use known information about particular fragment placement to

guide docking.”

The breadth and depth of scientific application in SYBYL-X remains unrivaled, with

emphasis on lead identification and optimization, and including capabilities for

cheminformatics, and small molecule as well as macromolecule modeling and

simulation.

According to Patrick Flanagan, Tripos’ Chief Operating Officer, “Tripos continues to

innovate scientifically, and to invest in workflow improvements that will help scientists be

more productive than ever in today’s competitive environment. Our continued focus on

providing easier ways to access the well-validated, robust science offered in SYBYL-X,

coupled with the simplicity of purchasing options and single price point for the entire

suite, combine to make SYBYL-X the most affordable, cost-effective life science

molecular modeling solution available today. ”

SYBYL-X is available today for Windows® and Linux®.

For more information, visit www.tripos.com/sybylx

About Tripos

Tripos, a Certara™ Company, is a global leader in innovative scientific software

products and services enabling life science researchers to improve the efficiency of

molecular discovery. Established in 1979, Tripos helps a broad range of companies

and research facilities accelerate the identification and optimization of new compounds

that have the potential to become marketed drugs, foods, flavorings and fragrances.

About Certara

Certara is dedicated to improving human health through a broad spectrum of products

and services, from molecular discovery to clinical research. Formed in 2008, Certara

unites Tripos and Pharsight Corporation, leading providers of software and scientific

services to improve productivity and decision-making in discovery and clinical drug

development. More information about Certara is available at www.certara.com.